Could Lab-Grown arteries replace vein grafts in heart bypass surgery?

NCT ID NCT07730528

Not yet recruiting Disease control Sponsor: Humacyte, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This trial tests whether a lab-grown, tissue-engineered blood vessel can be safely used as a bypass graft in people with coronary artery disease undergoing heart bypass surgery. Ten participants will receive the artificial vessel alongside a standard graft, and researchers will monitor how well it stays open and whether any complications arise over three years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a lab-grown tissue-engineered blood vessel called the Coronary Tissue Engineered Vessel (CTEV)
What this could lead to: If successful, this could provide a ready-made, off-the-shelf bypass graft that avoids the need to harvest a vein from the patient's own leg or arm.
What could go wrong: This is a very early, small trial with only 10 participants, so results may not apply widely. The graft could fail to stay open or cause blood clots or other complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE

More trials for these conditions

Other studies related to the condition(s) this trial covers.